data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Zymeworks
(NYSE:ZYME)
$5.695
0.155[2.80%]
Last update: 11:13AM
Day High/Low5.3 - 5.76
52 Week High/Low4.56 - 39.41
Open / Close5.39 / -
Float / Outstanding57.7M / 57.8M
Vol / Avg.371.2K / 2M
Mkt Cap329M
P/E-
50d Avg. Price5.98
Div / Yield-
Payout Ratio-
EPS-1.18
Total Float57.7M

Zymeworks (NYSE:ZYME), Quotes and News Summary

Zymeworks (NYSE: ZYME)

Day High/Low5.3 - 5.76
52 Week High/Low4.56 - 39.41
Open / Close5.39 / -
Float / Outstanding57.7M / 57.8M
Vol / Avg.371.2K / 2M
Mkt Cap329M
P/E-
50d Avg. Price5.98
Div / Yield-
Payout Ratio-
EPS-1.18
Total Float57.7M
Benzinga - Jun 14, 2022, 10:56AM
Benzinga - May 27, 2022, 10:27AM
Benzinga - May 27, 2022, 6:19AM
Benzinga - May 26, 2022, 5:09PM
Benzinga - May 23, 2022, 6:26AM
Benzinga - May 20, 2022, 3:13PM
Benzinga - May 20, 2022, 9:16AM
Benzinga - May 19, 2022, 1:04PM
Benzinga - May 9, 2022, 6:57AM
Benzinga - May 5, 2022, 6:39AM
Benzinga - May 4, 2022, 4:26PM
Benzinga - May 3, 2022, 3:28PM
Benzinga - May 3, 2022, 2:40PM
Benzinga - May 2, 2022, 5:15PM
Benzinga - May 2, 2022, 5:00PM
Benzinga - May 2, 2022, 12:58PM
Benzinga - Apr 29, 2022, 10:11AM
Benzinga - Apr 29, 2022, 6:12AM
Benzinga - Apr 28, 2022, 5:00PM
Benzinga - Apr 28, 2022, 4:34PM
load more
Sector: Health Care.Industry: Biotechnology
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-03
REV
Q1 2022Est.ActualSurprise
EPS-1.670-1.190 0.4800
REV3.470M1.916M-1.554M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Zymeworks Questions & Answers

Q
How do I buy Zymeworks (ZYME) stock?
A

You can purchase shares of Zymeworks (NYSE: ZYME) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Zymeworks's (ZYME) competitors?
Q
What is the target price for Zymeworks (ZYME) stock?
A

The latest price target for Zymeworks (NYSE: ZYME) was reported by SVB Leerink on Friday, May 27, 2022. The analyst firm set a price target for 19.00 expecting ZYME to rise to within 12 months (a possible 233.63% upside). 11 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Zymeworks (ZYME)?
A

The stock price for Zymeworks (NYSE: ZYME) is $5.695 last updated Today at July 5, 2022, 3:13 PM UTC.

Q
Does Zymeworks (ZYME) pay a dividend?
A

There are no upcoming dividends for Zymeworks.

Q
When is Zymeworks (NYSE:ZYME) reporting earnings?
A

Zymeworks’s Q2 earnings are confirmed for Wednesday, August 3, 2022.

Q
Is Zymeworks (ZYME) going to split?
A

There is no upcoming split for Zymeworks.

Q
What sector and industry does Zymeworks (ZYME) operate in?
A

Zymeworks is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.